All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CEA (MFZ) h(28OXζ), which is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CEA antibody linked to a CD28 transmembrane domain/ endodomain and OX40, CD3-zeta signaling domains. And the vector product was designed for the treatment of Pancreatic cancer.
CAR Construction : MFZ scFv-28ζ Fig.1 Both CD4 and CD8 T cells were modified with the CAR and used for adoptive transfer in this study CAR expression was monitored by flow cytometry using a phycoerythrin-labeled anti-mouse IgG1 antibody and an allophycocyanin-conjugated antibody directed against CD4 and CD8. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : MFZ scFv-28ζ Fig.2 T cells with anti-CEA CAR were coincubated at the indicated effector-to-tumor cell ratios with Panc02 cells with or without CEA expression for 48 hours. Cytotoxicity was assessed by an XTT-based viability assay. All measurements were performed in triplicate. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : MFZ scFv-28ζ Fig.3 Lung epithelia cells were isolated from the lung of CEAtg mice. Cells were stained for CEA and flow sorted before use in the study. Mouse CEA Panc02 pancreatic carcinoma cells and fibrosarcoma CEA C15A3 cells were used for comparison. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : MFZ scFv-28ζ Fig.4 CEA Panc02 pancreatic carcinoma cells were inoculated into the pancreas of CEAtg mice. After 3 weeks, the tumor tissue, as well as the healthy pancreas (without tumor), were recorded by H&E and CEA staining. The CEAtg mouse expressed CEA in transplanted CEA+ Panc02 pancreatic carcinoma as well as in healthy tissues. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
CAR Construction : MFZ scFv-28ζ Fig.5 Regression of transplanted pancreas carcinoma upon adoptive therapy with anti-CEA CAR T cells. CBLuc-marked Panc02 tumor cells and GLuc-marked T cells were recorded by bioluminescence imaging in the same mouse at the indicated days before and after T-cell transfer. Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt–Wolf, I. H., Hombach, A. A., & Abken, H. (2012). T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology, 143(4), 1095-1107. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CEA (MFZ) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX358). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION